The ESMO Congress is the most influential oncology platform for clinicians, researchers, patient advocates, journalists, and healthcare industry representatives worldwide. The annual event dedicated to presenting and discussing new findings in cancer treatment, research, and care will be held as a fully onsite event in Paris from 9 to 13 September 2022.
With the DelveInsight team in attendance, a golden networking opportunity will be present in hand that will eventually lead to a strong network connection from industrial personnel globally. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO creates a platform for learning and discussing current and future issues in the oncology domain.
Our researchers will be covering scientific meetings, professional workshops, educational sessions, and special symposia on issues of particular relevance and importance to clinical oncologists and researchers. Thousands of scientific abstracts will be released at the ESMO Congress, with the latest updates and findings from cancer clinical trials, which also include new drug studies, and can possibly change the perspective of cancer patient care. With these findings we will be updating our market forecast reports to include the breakthrough information.
Schedule A One-To-One Meeting with Our Delegates At ESMO 2022, Congress in Paris on 9 to 13th September 2022.
Meet us simply by filling up the form on the right.
DelveInsight’s Oncology Portfolio Management services provide exceptionally unmatched assistance in understanding competencies in the oncology market. In addition to that, we prioritize strategic goals, assess the changes in the oncology industry, understand the current needs of the cancer market and likewise work on creating value for client services.
DelveInsight aims at providing effective reports that tally with the rare cancer market. Our analysts track developmental, regulatory & commercial milestones of competitor products. It includes aspects such as conference assessment, and company and R&D development assessment to carry out the desired development of oncological products for commercial purposes dealing with the client’s area of interest.
Our multidimensional, purposeful, and credible consultancy services will help in accelerating oncology product services, it includes aspects such as congress intelligence, conference coverage, CI asset/indication tracking, brand presence and penetration assessment, drug therapy uptake, diagnostic landscape assessment to overcome several challenges in the oncology market.
We have a specialized primary Competitive Intelligence research team that has expertise in the field of oncology. It constitutes analysts, senior analysts, and managers. Our CI force provides the best possible opportunities and most accurate intelligence that can be accumulated and provided to our partners. In addition, exceptionally well and a collection of cancer data with a fundamental goal of acquiring best-in-class intelligence and providing oncology analysis with respect to different cancer therapeutics to achieve the consultation goal of our partners.
Our research and development analyst understands the oncology realm to create value-based decisions and help clients achieve better oncological R&D endeavors. Any oncological drug's journey through pre-clinical and clinical development is done by assessing the same parameters of other candidates already in the space. DelveInsight’s insight-packed oncological reports provide clarity on uncertainties and challenge blind spots to provide timely intelligence to the company.
DelveInsight’s Oncological Pipeline Assessment promises an overarching view of cancer therapies, their clinical trials, as well as each and every highlight of the cancer therapeutics landscape in a report format. Encompassing oncology ready reports already present in our Report Store, our Pipeline Assessment report type provides insights across therapies, MoAs, Drugs, APIs, as well as Launch Insights of drugs in late-stage of development to provide an understanding of their launch timelines and strategies.
We welcome you to discuss your business-related concerns and we can together find the best possible solution to help you proceed further in the Biotechnology and Pharma market.
Ms. Sadaf Javed is currently working in the Forecasting team with experience of almost 6 years in hand and expertise in creating indication-based pharma forecasting dynamic models. They include important categories such as disease epidemiology analysis, current market sales analysis, and upcoming market sizing estimations. An exceptionally skilled consultant, she is also involved in client interaction and has worked in several therapeutic areas including Neurological disorders, rare indications, autoimmune disorders, and Oncology. In addition to that, her responsibility extends by covering many International Oncology Conferences such as ASCO, and ESMO.
Rajesh is an extremely enthusiastic and dedicated professional who is self motivated, hard working and having decision making ability. With more than 10+ years of experience in market research having expertise in Market intelligence, BD&L, Strategic Planning and Forecasting. Throughout these years his major focus was Oncology and Rare Diseases space.
The ESMO 2022 conference and exhibition will take place from 9th to 13th of September, 2022 with an in-person meeting attendance in the dynamic city of paris, France.
